Evaluation of a change in cytomegalovirus prevention strategy following pediatric solid organ transplantation

Transpl Infect Dis. 2020 Apr;22(2):e13232. doi: 10.1111/tid.13232. Epub 2019 Dec 30.

Abstract

Background: An optimal cytomegalovirus (CMV) prevention strategy following solid organ transplantation (SOT) remains uncertain. This study reports on the rates of CMV events following a change in a local prevention guideline involving increased surveillance, earlier transition to oral valganciclovir, and decreased CMV-immunoglobulin use.

Methods: A retrospective cohort study utilizing historical controls evaluated the rates of CMV invasive disease pre- and post-intervention among pediatric heart, liver, and kidney recipients. Outcomes were recorded for the 4 years pre- and post-intervention, 9/2009-10/2017. Logistic regression was used to estimate the risk of a CMV event.

Results: There was no difference in the rates of CMV invasive disease between the two study groups (P = 1). An increase in the detection of CMV events occurred (P = .04), predominantly asymptomatic CMV infection. This increase was independently associated with increased surveillance testing among high-risk heart and liver recipients, aOR 1.08 (1.06-1.12). Surprisingly, 28.9% of CMV events occurred during antiviral prophylaxis.

Conclusions: Modification of the local CMV prevention guideline did not result in an increase in CMV invasive disease. CMV events occurred while on prophylaxis, highlighting a potential difference from adult solid organ transplant (SOT) and emphasizing the potential need for monitoring on prophylaxis in the pediatric population.

Keywords: cytomegalovirus; pediatric; prevention; solid organ transplantation.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Antibodies, Viral / administration & dosage
  • Antiviral Agents / administration & dosage
  • Child
  • Child, Preschool
  • Cytomegalovirus
  • Cytomegalovirus Infections / prevention & control*
  • Female
  • Ganciclovir / administration & dosage
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage
  • Infant
  • Logistic Models
  • Male
  • Organ Transplantation / adverse effects*
  • Primary Prevention / methods*
  • Retrospective Studies

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • Immunoglobulins, Intravenous
  • cytomegalovirus-specific hyperimmune globulin
  • Ganciclovir